X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
APP13007 (clobetasol propionate) is a nanoparticle formulation of a steroid in development for the treatment of inflammation and pain after cataract surgery. Sosei Heptares will receive undisclosed milestone payments based on progression of Activus' pipeline.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Immunology Product Name: APP13007
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Sosei Group Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 06, 2024
Details:
APP13007 (clobetasol propionate) is a nanoparticle ophthalmic formulation of a steroid. It is approved for the treatment of post-operative inflammation and pain following ocular surgery.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Neurology Product Name: APP13007
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AimMax Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
Under the agreement, Cristália gets exclusive Brazilian rights for the commercialization of APP13007 (clobetasol propionate ophthalmic nanosuspension) for the treatment of inflammation and pain following ocular surgery.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Neurology Product Name: APP13007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cristália
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 26, 2024
Details:
Through the acquisition, Eyenovia has gained the exclusive U.S. rights to distribute and sell APP13007 (clobetasol propionate ophthalmic nanosuspension), a potent steroid for reducing the inflammation and pain associated with ocular surgery, which is under review by FDA.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Neurology Product Name: APP13007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eyenovia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 16, 2023
Details:
APP13007 (clobetasol propionate ophthalmic nanosuspension) is expected to provide ophthalmologists and ocular surgery patients with a compelling, rapid and sustained, and more convenient postoperative anti-inflammatory and pain relief solution.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Neurology Product Name: APP13007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AimMax Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2023
Details:
There were 26.5% of subjects who showed sustained anterior chamber cell (ACC) count = 0 (inflammation free) from post-operative day 8 (POD8) through POD15 in the APP13007 (clobetasol propionate) arm as compared to 5.1% in the placebo arm (p<0.001).
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Neurology Product Name: APP13007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AimMax Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
Data showed statisticallly-significant and clinically-meaningful improvement of inflammation and pain with twice-daily APP13007 compared to matching placebo, a regimen that is being evaluated in ongoing Phase 3 studies.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Neurology Product Name: APP13007
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AimMax Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
